REVIEW 2 major objections 4 minor 3 references
Evidence of epigenetic oncogenesis: a turning point in cancer research
T0 review · 2 major / 4 minor · reviewed 2026-08-12 · deepseek-v4-flash
Pith's one-line read A review of a 2024 Drosophila experiment argues that a transient loss of Polycomb repression, with no oncogenic mutation involved, can initiate tumors that grow and metastasize—meaning somatic mutations are neither necessary nor…
desk verdict A clear and useful review that overstates its central claim: 'failed to detect increased mutation rates' is not evidence that the fly tumors are mutation-free. read the letter →
The pith
A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.
The reading
What carries the argument
The load-bearing object is Polycomb Repressive Complex 1 (PRC1), the chromatin-repressing machinery that keeps developmental genes stably silenced in differentiated cells. The experimental mechanism is a transient, inducible depletion of PRC1: once repression is released, irreversible activation of a small set of targets—the fly ZEB1 ortholog and JAK-STAT pathway components, with JNK signaling—commits cells to a tumor fate. Conceptually, the machinery is the contrast between the oncogene paradigm, which puts mutations first, and epigenetic oncogenesis, which puts a transient chromatin state first.
What would settle it
A definitive test would be a mammalian experiment: apply transient, inducible PRC1 silencing to adult mouse tissue, then reverse it, and watch for tumors. The review's claim predicts stable, metastasizing tumors with a normal mutation burden; if none appear, or if they appear only when a mutation is also present, the claim that epigenetic events alone can initiate mammalian cancer would be refuted.
Extended reading notes
Core claim
The central claim is that oncogenesis can be purely epigenetic: a transient perturbation of chromatin, not a DNA mutation, is enough to create a stable, metastasizing tumor. The evidence is a Drosophila experiment in which inducible silencing of PRC1 is applied briefly and then released; while most chromatin changes revert, a few targets—including the fly ortholog of ZEB1 and components of JAK-STAT signaling—stay activated, driving proliferation and epithelial-mesenchymal transition. Because these tumors formed without elevated mutation rates, the review concludes that genetic alterations are neither sufficient nor necessary for cancer initiation. This conclusion is presented as a turning point that reframes earlier non-genetic cancer theories—tissue disruption, gene-network attractors, and cellular stochasticity—as compatible precursors to what the fly experiment now demonstrates.
Load-bearing premise
The entire argument rests on the assumption that a temporary, laboratory-induced silencing of a gene-repressing complex in a fly—an organism that lacks DNA methylation—stands in for naturally occurring epigenetic cancer initiation in mammals, where no natural trigger for such a loss has yet been found.
Editorial extensions
If this is right
- If the central claim holds, cancer risk assessment must consider chromatin-altering, non-mutagenic effects of chemicals, not only DNA damage.
- The age-related rise in cancer risk would be partly explained by epigenetic drift and chromatin destabilization, not solely by accumulated mutations.
- Tumors with few or no recurrent mutations cease to be anomalies and become an expected class of epigenetically initiated cancers.
- Therapeutic strategies could target reversible epigenetic states early, potentially preventing transformation before any mutation appears.
- Models of early oncogenesis must include tissue disruption, inflammation, and cell-cell communication changes as possible initiating events, matching the high-plasticity states seen in single-cell studies.
Reading between the lines
- An implication the review leaves implicit: if a transient epigenetic hit can lock in a tumor fate, 'hit-and-run' carcinogenesis could explain cancers appearing years after exposure to non-mutagenic agents, without a matching mutational signature.
- A direct extension would be to repeat the experiment in human organoids with reversible epigenome editing at Polycomb targets; success would test whether the fly mechanism transfers to human epithelial tissue.
- The logic implies that non-mutagenic stressors—chronic inflammation, mechanical tissue disruption, or metabolic shifts—could be formally treated as epigenetic initiators in risk models, which would change how environmental carcinogens are identified.
- If correct, the classic initiation-promotion distinction may need revision: transient epigenetic change could be the initiating hit, with later mutations acting as passengers or stabilizers of an already committed tumor state.
Editorial analysis
A structured set of objections, weighed in public.
Referee Report
Summary. This perspective/review article argues that the recent study by Parreno, Cavalli and colleagues (Nature, 2024) provides the first direct demonstration that cancer can be initiated purely by transient epigenetic perturbations, in the absence of oncogenic mutations. The authors review the historical context of cancer epigenetics, recent single-cell and multi-omics studies of tumor evolution, and several alternative theoretical frameworks (TOFT, tissue disruption models, attractor theory), and they propose that the fly experiment marks a 'turning point' that should motivate searches for natural triggers of Polycomb loss and for non-mutagenic carcinogens. The paper's central claim is that somatic mutations are 'neither sufficient, nor necessary' for oncogenesis and that 'epigenetic events alone can be the triggering events.'
Significance. If the central claim were fully supported, the paper would be an important synthesis: it situates Parreno et al. in a long history of epigenetic cancer theory, connects recent single-cell data on chromatin accessibility and phenotypic plasticity to epigenetic initiation, and identifies concrete research directions (non-mutagenic carcinogens, aging and epigenome, tissue-disruption-induced Polycomb changes). The paper is well written and benefits from a broad reference list. Its main weakness is that the load-bearing statement—that the fly experiment 'demonstrates' mutations are neither sufficient nor necessary—overreaches the evidence, as the authors themselves acknowledge in their caveats that the experiment was artificial and that natural triggers in mammals are unknown. The manuscript would be acceptable after a major revision that recalibrates the strength of the conclusions to match the evidence.
major comments (2)
- [Other examples of studies questioning the oncogene paradigm, last paragraph] The sentence 'Cavalli and colleagues' work now demonstrates that they are neither sufficient, nor necessary' is not supported by the cited evidence. The primary data from Parreno et al., as described in the section 'The first direct evidence of epigenetic oncogenesis,' consist of a report that the authors 'failed to detect increased mutation rates.' A failure to detect an increase in mutation rate is not equivalent to demonstrating the absence of mutations, and in particular does not rule out a small number of pre-existing or de novo driver mutations that could cooperate with the epigenetic changes. The manuscript's own suggestion that ZEB1's DNA-repair function 'could contribute to tumorigenesis while preventing the accumulation of a high mutational burden' is an untested hypothesis, not a demonstrated mechanism. Without whole-genome sequencing evidence that the fly tumors carry no oncogenic mutations, the categorical 'demonstrates' claim overreaches; the conclusion should be rephrased as, for example, 'challenges the necessity of mutations' or 'suggests that epigenetic events alone can be sufficient in this experimental system.'
- [The first direct evidence of epigenetic oncogenesis, last paragraph] The authors themselves write that 'this transient repression of Polycomb was obtained in a fairly artificial way' and that 'it would be fundamental to identify possible causes of a naturally occurring transient loss of Polycomb PRC1 complex functions.' Yet the paper's title and conclusion ('Epigenetic events alone can be the triggering events') generalize from an artificial, inducible PRC1 knockdown in Drosophila—a species that lacks DNA methylation—to naturally occurring human cancer. The forward-looking sections ('What can cause epigenetic alterations able to induce cancers?') propose that dietary, metabolic, toxicological, or mechanical disruptions could reproduce this effect in mammals, but they provide no direct evidence that such natural transient PRC1 loss occurs or that it would be sufficient for tumor initiation in a mammalian context. The gap between the artificial fly experiment and natural human oncogenesis should be reflected in the central claim itself, not merely relegated to a caveat paragraph.
minor comments (4)
- [Other examples of studies questioning the oncogene paradigm, last paragraph] For consistency, 'Cavalli and colleagues' work' should be 'Parreno et al.'s work,' since the authors refer to 'Parreno et al.' throughout the rest of the manuscript.
- [References, ref. 62] Reference 62 (Hunter et al.) is a bioRxiv preprint; if the journal permits citation of preprints, this should be explicitly noted, and the phrase 'bioRxiv' should appear in the reference itself or in the text; otherwise a peer-reviewed version should be cited.
- [Introduction, paragraph 1] The phrase 'by imposing a transient loss of Polycomb repression by inducible silencing of PRC1, removing a fundamental complex' is awkward; 'removing' should be 'silencing' or 'depleting' to avoid implying that a protein complex is physically removed from the genome.
- [What can cause epigenetic alterations able to induce cancers?] The theoretical sections (e.g., the TiDiS hypothesis and the role of tissue disruption) rely heavily on the authors' own prior publications (refs 56-59 and 12) without independent validation; these should be presented as speculative extensions of the main argument rather than established support for the central claim.
Circularity Check
No significant circularity: the central claim rests on an external experimental result, and the paper's own self-citations are contextual rather than load-bearing.
full rationale
The paper is a perspective piece, not a derivation. Its central assertion that 'epigenetic events alone can be the triggering events' rests on the externally published Drosophila experiment of Parreno et al. (Nature 629:688-96), cited as reference 32, not on any quantity defined or fitted in this paper. The authors explicitly locate the load-bearing demonstration outside their own work: 'Now Parreno, Cavalli and colleagues... enforced the initiation of tumours solely by imposing a transient loss of Polycomb repression.' They also disclose the limits of the evidence: 'this transient repression of Polycomb was obtained in a fairly artificial way' and note the caveat of 'the absence of DNA methylation in the model organism.' The self-citations to Capp (2005, 2017, 2020, 2021) and Pancaldi (2021) appear as historical or compatible hypotheses (e.g., the TiDiS theory), not as proof of the fly result; none of these citations is used to define the term 'epigenetic oncogenesis' or to substitute for the external experimental evidence. Because no fitted parameter is renamed as a prediction and no equation reduces to an input, there is no circular step. The concern that 'failed to detect increased mutation rates' does not prove mutation-free tumors is a correctness/interpretation concern, not a circularity concern.
Assumptions & free parameters
assumptions (4)
- domain assumption Drosophila PRC1 depletion models human oncogenesis despite the absence of DNA methylation in flies.
- domain assumption The induced epigenetic changes in flies are stably inherited across cell divisions, similar to epigenetic inheritance in mammals.
- domain assumption Pathway activation patterns (JAK-STAT, ZEB1, JNK) in flies correspond functionally to the same pathways in human cancers.
- domain assumption Correlational single-cell chromatin data from human tumors (refs 40, 41) can be interpreted as evidence for epigenetic initiation, not just correlation.
Cite this review
Pith. "Pith review of Evidence of epigenetic oncogenesis: a turning point in cancer research." pith.science (2026). https://pith.science/paper/5NIQRB77
@misc{pith2026241114130,
author = {Pith},
title = {Pith review of: Evidence of epigenetic oncogenesis: a turning point in cancer research},
year = {2026},
howpublished = {\url{https://pith.science/paper/5NIQRB77}},
note = {Machine review of arXiv:2411.14130}
}
read the original abstract
In cancer research, the term epigenetics was used in the 1970s in its modern sense encompassing non-genetic events modifying the chromatin state, mainly to oppose the emerging oncogene paradigm. However, starting from the establishment of this prominent concept, the importance of these epigenetic phenomena in cancer rarely led to questioning the causal role of genetic alterations. Only in the last 10 years, the accumulation of problematic data, better experimental technologies, and some ambitious models pushed the idea that epigenetics could be at least as important as genetics in early oncogenesis. Until this year, a direct demonstration of epigenetic oncogenesis was still lacking. Now Parreno, Cavalli and colleagues, using a refined experimental model in the fruit fly Drosophila melanogaster, enforced the initiation of tumours solely by imposing a transient loss of Polycomb repression, leading to a purely epigenetic oncogenesis phenomenon. Despite a few caveats that we discuss, this pioneering work represents a major breakpoint in cancer research that leads us to consider the theoretical and conceptual implications on oncogenesis and to search for links between this artificial experimental model and naturally occurring processes, while revisiting cancer theories that were previously proposed as alternatives to the oncogene-centered paradigm.
Reference graph
Works this paper leans on
-
[1997]
From the regulatory vision of cancer to the oncogene paradigm, 1975-1985. J Hist Biol 30: 1-29. 18 Feinberg AP , Vogelstein B
work page 1975
-
[2019]
Cancer Stem Cells: From Historical Roots to a New Perspective. J Oncol 2019: 5189232. 5 Nicoglou A, Merlin F
work page 2019
-
[2024]
Mechanical confinement governs phenotypic plasticity in melanoma. bioRxiv: 2024.01.30.577120. 63 Ciriello G, Magnani L, Aitken SJ, Akkari L, et al
work page 2024
Reviewed August 12, 2026 · model on record in the stance chip above.
Discussion (0). Continue with ORCID to comment.